Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic...
Non-infectious Macular Edema Treatment Market | AbbVie, Alimera Sciences, Allergan
ZENTEK LTD. 24 Corporate Court Guelph, Ontario N1G 5G5 NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY...
Altium Capital Management LP, a New York-based investment firm, recently made a significant move in the stock market by acquiring a new stake in Alimera Sciences Inc. This article provides an in-depth analysis of the transaction, the profiles of both entities, and the potential implications of this strategic move. On August 15, 2023, Altium Capital Management LP purchased 2,984,803 shares of Alimera Sciences Inc at a price of $3.57 per share. This acquisition had a 7.46% impact on the firm's portfolio, making it a significant transaction.
Alimera Sciences (NASDAQ:ALIM – Get Free Report) and Summit Therapeutics (NASDAQ:SMMT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk. Profitability This table compares Alimera Sciences and […]